AbbVie Inc ABBV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ABBV is a good fit for your portfolio.
News
-
AbbVie Shares Close Down 4.6%, Sees Additional Humira Volume Erosion in 2Q
-
AbbVie Lifts Outlook After 1Q Revenue Unexpectedly Rises
-
AbbVie's first-quarter results top expectations as arthritis drugs fuel growth
-
AbbVie Study on Treatment for Giant Cell Arteritis Meets Primary Endpoint
-
Medincell, AbbVie to Co-Develop Injectable Therapeutics
-
AbbVie on Pace for Largest Percent Decrease Since October 2023 — Data Talk
-
Landos Biopharma Shares Surge 178% on Takeover Deal With AbbVie
-
AbbVie in Deal to Acquire Landos Biopharma for $137.5 Million
Trading Information
- Previous Close Price
- €149.40
- Day Range
- €149.30–149.78
- 52-Week Range
- €119.50–168.66
- Bid/Ask
- €0.00 / €0.00
- Market Cap
- €263.64 Bil
- Volume/Avg
- 0 / 0
Key Statistics
- Price/Earnings (Normalized)
- 14.78
- Price/Sales
- 5.28
- Dividend Yield (Trailing)
- 3.75%
- Dividend Yield (Forward)
- 3.63%
- Total Yield
- 4.22%
Company Profile
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 50,000
- Website
- http://www.abbvieinvestor.com
Competitors
Valuation
|
Metric
|
ABBV
|
LLY
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 14.78 | 81.28 | 59.70 |
Price/Book Value | 35.55 | 56.38 | 8.13 |
Price/Sales | 5.28 | 19.11 | 5.37 |
Price/Cash Flow | 15.27 | 79.41 | 18.89 |
Price/Earnings
ABBV
LLY
MRK
Financial Strength
|
Metric
|
ABBV
|
LLY
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.72 | 0.68 | 0.68 |
Current Ratio | 0.94 | 1.35 | 1.25 |
Interest Coverage | 3.95 | 14.11 | 3.97 |
Quick Ratio
ABBV
LLY
MRK
Profitability
|
Metric
|
ABBV
|
LLY
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 14.14% | 11.20% | 5.22% |
Return on Equity (Normalized) | 172.29% | 57.69% | 13.56% |
Return on Invested Capital (Normalized) | 27.87% | 20.65% | 8.29% |
Return on Assets
ABBV
LLY
MRK
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Znsgptcb | Tryj | $733.3 Bil | |
JNJ
| Johnson & Johnson | Jzxdxsqtv | Smzv | $360.8 Bil | |
MRK
| Merck & Co Inc | Hdqnrjsyv | Wvxxs | $329.8 Bil | |
ABBV
| AbbVie Inc | Wysspxmx | Zjxv | $283.3 Bil | |
AZN
| AstraZeneca PLC ADR | Pnjtrwrxx | Jznjf | $237.7 Bil | |
NVS
| Novartis AG ADR | Jryvqnzww | Hprq | $203.4 Bil | |
RHHBY
| Roche Holding AG ADR | Xlhpcvbnx | Lrtp | $197.6 Bil | |
AMGN
| Amgen Inc | Vhxxmfkvm | Jysd | $166.4 Bil | |
PFE
| Pfizer Inc | Rfjkwtdy | Bzlrq | $159.7 Bil | |
SNY
| Sanofi SA ADR | Vbvxsqxz | Mxzm | $125.1 Bil |